Table 1.
Baseline patient characteristics
| Characteristics | Nonrecently treated control | B-lymphoid malignancies off therapy | Recently treated control | Recently treated B-lymphoid malignancies |
|---|---|---|---|---|
| (n = 4111) | (n = 479) | (n = 3653) | (n = 516) | |
| Cancer status | ||||
| Remission/NED | 71% (2901) | 56% (266) | 23% (837) | 27% (137) |
| Active, stable or responding | 14% (555) | 29% (137) | 47% (1706) | 45% (232) |
| Active, progressing | 8% (311) | 6% (31) | 21% (777) | 16% (81) |
| Unknown | 8% (342) | 9% (44) | 9% (326) | 13% (66) |
| Missing | 0% (<5) | 0% (<5) | 0% (7) | 0% (<5) |
| Age [years, median (IQR)] | 67 (57–77) | 63 (52.5–74) | 63 (53–72) | 62 (47–73) |
| Sex | ||||
| Female | 50% (2073) | 43% (204) | 58% (2108) | 41% (211) |
| Male | 49% (2034) | 57% (275) | 42% (1544) | 59% (304) |
| ECOG performance status | ||||
| Zero | 33% (1360) | 41% (194) | 34% (1225) | 30% (157) |
| One | 17% (717) | 20% (97) | 35% (1265) | 38% (196) |
| Two or greater | 12% (513) | 10% (48) | 16% (576) | 15% (75) |
| Unknown | 37% (1517) | 29% (140) | 16% (576) | 17% (87) |
| Missing | <1% (<5) | <1% (<5) | <1% (11) | <1% (<5) |
| Smoking status | ||||
| Never | 52% (2119) | 58% (277) | 53% (1953) | 59% (305) |
| Current or former | 46% (1889) | 38% (183) | 43% (1569) | 37% (190) |
| Missing | 3% (103) | 4% (19) | 4% (131) | 4% (21) |
| Modified Charlson Comorbidity index (median, IQR) | 2 (1–3) | 2 (1–3) | 1 (1–2) | 1 (1–2) |
| Timing of COVID-19 diagnosis | ||||
| Jan–Apr 2020 | 25% (1039) | 26% (125) | 23% (829) | 27% (137) |
| May–Aug 2020 | 40% (1653) | 43% (205) | 41% (1505) | 37% (191) |
| Sep–Dec 2020 | 20% (832) | 19% (90) | 20% (746) | 20% (102) |
| Jan–Apr 2021 | 14% (555) | 12% (58) | 15% (534) | 15% (79) |
| May–Aug 2021 | 1% (23) | <1% (<5) | 1% (23) | 1% (<5) |
| Missing | <1% (9) | <1% (<5) | <1% (16) | <1% (<5) |
| Race | ||||
| Non-Hispanic White | 56% (2302) | 58% (276) | 49% (1801) | 50% (259) |
| Hispanic | 13% (514) | 15% (71) | 19% (703) | 24% (122) |
| Non-Hispanic Black | 19% (787) | 14% (66) | 18% (669) | 14% (70) |
| Other | 11% (449) | 12% (59) | 11% (401) | 12% (61) |
| Missing | 1% (59) | 1% (7) | 2% (79) | 1% (<5) |
| Obesity | ||||
| Not obese | 60% (2460) | 66% (317) | 63% (2294) | 62% (322) |
| Obese | 40% (1636) | 34% (161) | 36% (1329) | 37% (191) |
| Missing | <1% (15) | <1% (<5) | 1% (30) | <1% (<5) |
| Region | ||||
| U.S. Northeast | 31% (1278) | 39% (187) | 41% (1482) | 42% (219) |
| U.S. Midwest | 32% (1333) | 25% (118) | 20% (746) | 21% (106) |
| U.S. South | 15% (597) | 15% (70) | 17% (607) | 18% (95) |
| U.S. West | 19% (763) | 17% (82) | 17% (625) | 15% (78) |
| Other | 3% (140) | 5% (22) | 5% (193) | 3% (18) |
| Vaccination status | ||||
| Any vaccine before COVID-19 | 1% (50) | 1% (6) | 2% (57) | 3% (15) |
| No vaccine before COVID-19 | 30% (1213) | 27% (129) | 29% (1065) | 30% (155) |
| Unknown | 3% (111) | 3% (15) | 3% (102) | 2% (100) |
| Missing | 67% (2737) | 69% (329) | 66% (2429) | 65% (336) |
NOTE: These are intended to avoid potential identification of patients based on relatively rare permutations of variables. To this end, data are only presented for categories in which displaying these outcome data is feasible without violation of this standard, to protect patient privacy.
Abbreviations: ECOG, Eastern Cooperative Oncology Group. Counts less than 5 are not presented pursuant to CCC19 consortium publication standards; NED, no evidence of disease.